SCHEMBL16245487

SCHEMBL16245487

CCc1cccc(-c2n[nH]cc2-c2nc3ccccc3s2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.46
MAPT P10636 6/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
NFKB1 P19838 3/20 0.46
NFKB2 Q00653 3/20 0.46
RELA Q04206 3/20 0.46
TDP1 Q9NUW8 3/20 0.46
KDM4E B2RXH2 8/20 0.44
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
ALDH1A1 P00352 5/20 0.44
GAA P10253 2/20 0.44
GLA P06280 2/20 0.44
HCRTR1 O43613 1/20 0.44
ILK Q13418 4/20 0.44
NPC1 O15118 6/20 0.43
PKM P14618 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21351047 0.82 RAB9A (0.61) RAB9AMAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL715973 0.82 ILK (0.54) RAB9AMAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL687680 0.77 ILK (0.64) RAB9AMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL687376 0.76 KDM4E (0.68) RAB9AMAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL686897 0.75 KDM4E (0.64) RAB9AMAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL686516 0.73 ALDH1A1 (0.61) RAB9AMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL687432 0.73 ILK (0.56) RAB9AMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL686476 0.73 ILK (0.57) RAB9AMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL687435 0.72 KDM4E (0.71) RAB9AMAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL17696371 0.72 AGPAT2 (0.52) RAB9AMAPTSMN1; SMN2TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434720-B2 Pyrazolylbenzothiazole derivatives and their use as therapeutic agents DIRMIRA (CANADA), INC. (US) 2016-09-06 US disclosed
US-20140350009-A1 PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS DERMIRA (CANADA), INC. (US) 2014-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140350009-A1 PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS COXFA4L2, TYR, XDH RAB9A 3096/4885MAPT 865/4885SMN1; SMN2 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.